The firm plans to use the proceeds to expands its commercial operations, expand its existing technology, and support the launch of its new platform.
The cell-based diagnostics firm sold a total of 2.76 million shares, including 360,000 shares to the offering's underwriter.
The cancer diagnostics company went public today on the Nasdaq with an initial public offering of 2.4 million shares, priced at $9.50 per share.
The cell-based cancer diagnostics firm said in an SEC filing that it plans to offer 2 million shares of its common stock at between $8 and $10 per share.
Its technology called CELx uses a patient's tumor cells to identify abnormal cellular activity driving their cancer and the most appropriate therapy.
The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said.
The firm began offering its common shares on Wednesday at $6 per share on the Nasdaq. Gross proceeds from the IPO were $7.1 million.
The molecular diagnostics firm said in an amended prospectus that it plans to offer 1.3 million shares of its common stock at between $6.35 and $6.75 per share.